Abstract
Objective: Study aimed to describe the effect of dexamethasone pulse therapy by assessing its efficacy on patients infected with COVID-19 complicated with MIS-C. Methods: This is single center, retrospective case series study that was conducted in Saudi Arabia. We report all eligible patients who diagnosed with MIS-C and received pulse therapy of dexamethasone during COVID-19 pandemic from 2020-2022. The study endpoints were success to wean or extubate the patient and discharge from the PICU. Results: Three patients were included in this report. All three patients received dexamethasone pulse therapy were successfully improved. After five to seven days were discharged from PICU. Conclusion: Our clinical experience suggests that the efficacy of dexamethasone with MIS-C as alternative to methylprednisolone could be effective.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Saudi Journal of Medical and Pharmaceutical Sciences
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
